Nonprofit Groups Work To Bring Device Companies Together For Supplier Accreditation
This article was originally published in The Silver Sheet
As the device industry looks to beef up supply chain quality, a pair of nonprofit organizations – Rx-360 and the Performance Review Institute – is offering manufacturers a chance to take part in programs that would allow for greater control over vendors. PRI’s initiative would focus its audits on vendors that provide manufacturers with five critical process-specific activities, while Rx-360’s program will dispatch auditors to review a supplier’s overall quality management system. In theory, firms that use either program will save resources because they could spend less time and money overseeing suppliers. In turn, vendors would welcome fewer manufacturer audits. But there is one lingering question: Should PRI and Rx-360 join forces? Former FDAer Steven Niedelman believes it could happen. “If a manufacturer participates in both programs, then they’ll have supplier control completely locked down,” he says.
You may also be interested in...
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.
Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug; FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.
FerGene bladder cancer therapy achieved a complete response in more than half of patients in its pivotal trial. The joint venture now looks to commercialization and potential expansion of indications.